Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

16.07 +0.54 (+3.48%)
Streaming Delayed Price Updated: 2:45 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 336,258
Open 15.37
Bid (Size) 16.06 (3)
Ask (Size) 16.07 (3)
Prev. Close 15.53
Today's Range 15.30 - 16.08
52wk Range 11.16 - 35.95
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire

Performance

YTD
-49.78%
-49.78%
1 Month
+5.86%
+5.86%
3 Month
-25.81%
-25.81%
6 Month
-44.61%
-44.61%
1 Year
-45.02%
-45.02%

More News

Read More
Expert Ratings For Pacira BioSciences
Via Benzinga
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Expert Ratings For Pacira BioSciences
Via Benzinga
NASDAQ:PCRX: good value for what you're paying.
Via Chartmill
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
Via Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
3 Biotech Stocks to Buy on the Dip: July 2024
Via InvestorPlace
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Via Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.